CIINBIO@EC2610A

Ede Ronald Hao Xi reduced holdings of Innovent Biologics to 1 million shares

Innovative Drug Margetide's Phase II Clinical Trial Results Published in Cell Journal

CICC Report Analyzes Innovent Biologics 2025 Performance and Provides Rating Recommendations

UBS Cuts CSB Biopharma EPS Forecast but Maintains Buy Rating

Citi Raises Rating and Target Price for Innovent Biologics

Goldman Sachs Report: Innovent Biologics Surpassed Revenue Expectations in H2 2022

INNOVENT BIO released FY2025 9 Months Earnings on March 26, 2026 (BJT) with actual revenue of HKD 6.446 B and EPS of HKD 0.5305

INNOVENT BIO released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.874 B, actual EPS HKD -0.0066

INNOVENT BIO released FY2025 Q4 earnings on March 26 After-Market (BJT), actual revenue HKD 3.941 B, actual EPS HKD -0.0067

INNOVENT BIO released FY2025 Annual Earnings on March 26 After-Market (BJT), Actual Revenue: HKD 14.25 B (Forecast: HKD 14.83 B), Actual EPS: HKD 0.5136 (Forecast: HKD 1.07)

Innovent Biologics Announces Profitable Year, Reversing Previous Losses

Innovent Biologics Clarifies Strategic Cooperation Agreement Not an Acquisition

JPMorgan Increases Stake in Innovent Biologics by 497,823 Shares

INNOVENT BIO to release FY2025 earnings on March 26 After-Market (BJT), forecast revenue HKD 15.22 B, EPS HKD 1.0976

JPMorgan Increases Stake in Innovent Biologics to 5%

Morgan Stanley Predicts China's Biotech Sector to Fluctuate in H1 and See Clearer Direction in H2

Innovent Biologics' Pirtobrutinib Receives Approval for New Indication

Innovent Biologics' Pirtobrutinib Approved for New Indication in CLL/SLL Patients

Innovent Biologics and Eli Lilly Partner to Advance Innovative Drug Development

Shanghai Pudong Development Bank Maintains Buy Rating on Innovent Biologics with Target Price

SOMERLEY CAP

DEEPEXI TECH

CH FRONTIER TEC

CHINA FORTUNE

INTELLIMARK W27

MOG DIGITECH

WANJIA GROUP

SAMPLE TECH

JAKOTA CAPITAL

CHAOWEI POWER

01801

00883

002594

JP Morgan released a report listing the latest preferred stocks of Chinese companies, all of which have been given a "buy" rating. The list includes CNOOC, target price HKD 33; BYD, target price HKD 120; Northern Huachuang, target price RMB 610; MINIMAX-W, target price HKD 1,100; Zhizhu, target price HKD 950; Bank of China, target price HKD 5.5; INNOVENT BIO, target price HKD 111

AASTOCKS

INNOVENT BIO

CNOOC

JP Morgan lists the latest preferred stocks of Chinese companies (Table)

ADMA

Innovent Biologics announced preclinical results of IBI3055, a tri-specific T cell engager targeting autoimmune diseases, at the 2026 Immune Resetting Summit. IBI3055 targets CD19, BCMA, and CD3, designed to balance immune cell depletion with safety. Preclinical studies show it effectively depletes B cells and plasma cells, demonstrating favorable tolerability. Innovent aims to address unmet medical needs in autoimmune diseases with innovative therapies. Founded in 2011, Innovent partners with over 30 global healthcare companies and has launched 18 products, with several in advanced clinical trials.

prnewswire

Adma Biologics

iShares Global Healthcare

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Inovio Pharma

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Abcellera Biologics

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

VG Health

20:00 ETImmune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases

159849

588130

516500

516820

517110

510660

589720

600276

159837

The 12th Annual China Healthcare Investment Conference (CHIC 2026) celebrated outstanding achievements in healthcare investment at its Awards Gala Dinner in Shanghai. The event recognized key players in the sector, awarding Insilico Medicine for IPO of the Year, and Kailera Therapeutics and Vor Bio for Private Financing of the Year. Hengrui Pharma-GSK and Innovent-Takeda shared the Deal of the Year award. The conference connects innovation and investment in China's healthcare, featuring leaders from venture capital, private equity, and the pharmaceutical industry.

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

Hengrui Pharma

E Fund CSI Biotechnology Theme ETF

20:00 ETCHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala

159859

159992

588860

588250

512010

516930

512290

CMB International released a research report, expecting INNOVENT BIO to achieve strong performance in the fiscal year 2025, with a net profit of RMB 834 million and total revenue of RMB 13 billion, a year-on-year increase of 38%. Product sales are expected to reach RMB 11.9 billion, a year-on-year increase of 45%. Based on INNOVENT BIO's innovation capabilities and global development potential, the rating is maintained at "Buy," with the target price slightly raised from HKD 110.62 to HKD 113.86

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

CITIC International slightly raised INNOVENT BIO's target price to 113.86 yuan, accelerating its transformation towards global biopharmaceuticals

513120

159102

159316

Innovent Biologics shares surged 7.7% after the company reported its first full year of profitability, with revenue rising 38% to over 10 billion yuan ($1.45 billion). The net profit reached 813.6 million yuan, a turnaround from a loss the previous year. Analysts remain optimistic about Innovent's growth, citing a strong pipeline of drug candidates and collaborations valued over $22 billion. The stock's rise coincided with a broader rally in Chinese healthcare stocks, with the Hang Seng biotech index climbing 5.2%.

marketscreener

Proshares UltraShort Nasdaq Biotech

Bosera Hang Seng Health Care ETF(QDII)

SPDR S&P Biotech

GF CSI HK Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai Hang Seng Biotech ETF

China Southern Hang Seng Biotech ETF(QDII)

Innovent Biologics Shares Surge After Swing to Profitability

01093

01772

03288

01276

01339

02097

06869

06690

03986

CSPC PHARMA(01093) rose 13.85%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 10.2%. GANFENGLITHIUM(01772) rose 9.26%, with a trading turnover 2.7 Billion HKD, and a year-to-date rose 43%. PICC GROUP(01339) fell 7.18%, with a trading turnover 746.4 Million HKD, and a year-to-date fell 19.6%. MIXUE GROUP(02097) fell 4.86%, with a trading turnover 354.1 Million HKD, and a year-to-date fell 30.2%.

Top Gainers & Losers

CSPC PHARMA

GANFENGLITHIUM

HAITIAN FLAV

HENGRUI PHARMA

PICC GROUP

MIXUE GROUP

YOFC

HAIER SMARTHOME

GIGADEVICE

Top 5 HK Stock Gainers/Losers (>100B) (3.27)

UBS has lowered the target price for INNOVENT BIO to 124 yuan, reiterating a "Buy" rating. The report indicates that INNOVENT BIO's revenue in the second half of last year was 7.1 billion yuan, an annual increase of 29.6%, with a net loss of 21 million yuan. The total revenue for the year was 13 billion yuan, with a net profit of 814 million yuan, successfully turning a profit. UBS has raised its spending forecast and lowered the earnings per share forecast for this year and next by 52% and 27%, respectively, but maintains its peak sales forecast unchanged

UBS lowers the target price of INNOVENT BIO to 124 yuan, reiterating a "Buy" rating

603127

The Hong Kong innovative drug sector continued to rise in the afternoon, with JOINN and CSPC PHARMA up over 10%, INNOVENT BIO up over 7%, and JUNSHI BIO and INNOCARE following suit

Wallstreetcn

JOINN

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

InnoCare Pharma

JUNSHI BIO

INNOCARE

Innovent Biologics' shares surged after the company announced its first annual profit, marking the largest increase in nearly five months. The Chinese pharmaceutical firm credited this success to the growing demand for its weight-loss medication, which has significantly boosted investor confidence and led to a notable rise in stock value.

CoinLive

Innovent's Shares Surge Following First Annual Profit Announcement

Goldman Sachs has slightly lowered the target price for INNOVENT BIO to RMB 102.84, maintaining a "Buy" rating. The company's revenue in the second half of last year reached RMB 7.09 billion, a year-on-year increase of 30%, exceeding expectations. Management is confident in achieving the sales revenue target of RMB 20 billion by 2027. Total operating expenses increased to RMB 6.2 billion, surpassing forecasts. Earnings per share forecasts have been adjusted down to RMB 0.99 and RMB 2.46, with a new earnings per share forecast for 2028 set at RMB 3.17

Goldman Sachs slightly lowered the target price for INNOVENT BIO to 102.84 yuan, maintaining a "Buy" rating

INNOVENT BIO achieved its first annual profit, with a net profit of 814 million RMB and a revenue of 13.042 billion RMB, a year-on-year increase of 38.4%. The stock price opened up 0.88% today, reaching a high of 85.55 RMB, currently reported at 84.7 RMB, an increase of 6.68%. The company's product portfolio has expanded to 18 products, of which 12 have been included in the national medical insurance. Three core innovative assets have entered global Phase III clinical trials, targeting a market of over 60 billion USD

INNOVENT BIO rose over 6%, recording its first annual profit of 814 million RMB

02269

Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

WUXI BIO

Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

Innovent Biologics posts FY profit RMB813.6 million

Innovent Biologics posts FY profit RMB813.6 million

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

WuXi Biologics

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

BITFIRE GROUP

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

OKG TECH

Interactive Media and Services

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

CIINBIO@EC2610A(28133.HK)

CIINBIO@EC2610A Stock Performance Chart

JP Morgan lists the latest preferred stocks of Chinese companies (Table)

20:00 ETImmune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases

20:00 ETCHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala

CITIC International slightly raised INNOVENT BIO's target price to 113.86 yuan, accelerating its transformation towards global biopharmaceuticals

Innovent Biologics Shares Surge After Swing to Profitability